Clearmind Medicine to Host “Psychedelic for Alcoholism: From Molecule to Medicine” Virtual Event on January 26

TORONTO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce it will be hosting Psychedelics For Alcoholism, a free, live virtual event highlighting Clearmind’s patented MEAI molecule "From Molecule to Medicine: The Clinical Trial Pathway".